[ad_1]
German pharmaceutical company CureVac announces disappointing mRNA test results COVID-19 vaccine, Frustrating hope that the jab will help meet the global demand for effective vaccination.
CureVac said on Wednesday that in an interim analysis of its late-stage trials, its injection vaccine was 47% effective in preventing coronavirus, making it one of the most ineffective coronavirus vaccines tested so far.
Earlier this week, US drugmaker Novavax stated that its protein-based injections are 90% effective In the fight against the coronavirus, Moderna and BioNTech/Pfizer’s vaccines are 95% effective against the original strain of the virus.
CureVac’s NASDAQ-listed stock plunged 50% in after-hours trading in New York.
The company attributed the disappointing results to new strains of the virus circulating in 10 countries in Latin America and Europe, where it conducted trials.
In a study of 40,000 people, Vacuum cleaner It is said that 13 mutations have been found in volunteers, and more than half of the coronavirus cases are caused by worrying mutations.
however, Data from the UK This week showed that the two-dose mRNA or messenger RNA vaccine of BioNTech/Pfizer’s competitors is 96% effective in preventing hospitalization of people infected with the Delta variant, which was discovered for the first time in India.
This week, the US Centers for Disease Control and Prevention added the Delta strain to its list of variants of interest.
CureVac has partnered with the German manufacturing conglomerate Bayer to produce its coronavirus vaccine, and has reached an agreement with the British pharmaceutical company GlaxoSmithKline to develop the next generation of vaccines.
The weak test results cast doubt on the feasibility of these projects. CureVac’s goal is to produce 300 million doses of vaccine this year and 1 billion doses in 2022.
CureVac CEO Franz-Werner Haas said: “While we hope to achieve stronger mid-term results, we recognize that it is challenging to demonstrate efficiency in this unprecedented wide variety of diversity.” He added, Many variations “emphasize the importance of developing next-generation vaccines.”
The vaccine is currently being studied in the UK as part of an enhanced trial involving different injections of people who have already received two doses of Oxford/AstraZeneca or BioNTech/Pfizer vaccines.
Like Moderna and BioNTech/Pfizer vaccines, CureVac’s jab uses mRNA, but its mRNA is natural and unmodified. Compared with Moderna’s 100mg and BioNTech/Pfizer’s 30mg, its injection dose is also lower, 12 micrograms, which reduces production costs and is stable at traditional refrigerator temperatures.
CureVac said it will continue to test its two doses of mRNA vaccines and will determine the most appropriate regulatory approach after evaluating the final test data.
Coronavirus business update
What is the impact of the coronavirus on the market, business, and our daily lives and workplaces? Keep up to date with our coronavirus newsletter. Register here
[ad_2]
Source link
